Media coverage about G1 THERAPEUTICS (NASDAQ:GTHX) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. G1 THERAPEUTICS earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.6200782527152 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at 24.65 on Friday. The stock’s market cap is $697.23 million. G1 THERAPEUTICS has a 1-year low of $12.04 and a 1-year high of $28.67. The firm has a 50-day moving average of $23.96 and a 200 day moving average of $18.76.
G1 THERAPEUTICS (NASDAQ:GTHX) last issued its earnings results on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.48). Equities research analysts forecast that G1 THERAPEUTICS will post ($2.92) earnings per share for the current year.
A number of equities research analysts recently weighed in on GTHX shares. Cowen and Company restated a “buy” rating on shares of G1 THERAPEUTICS in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $29.75.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect G1 THERAPEUTICS (GTHX) Share Price” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/10/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-g1-therapeutics-gthx-share-price.html.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.